| HOME >> BIOLOGY >> TECHNOLOGY |
PRINCETON, N.J., April 24 /PRNewswire-FirstCall/ -- Pharmasset, Inc. (Nasdaq: VRUS) management will present at the Morgan Stanley Global Healthcare Unplugged Conference being held from April 30, 2008 to May 2, 2008 at the Ritz-Carlton Key Biscayne in Miami, Florida. Schaefer Price, Pharmasset's Chief Executive Officer, will provide an overview of the company and participate in a discussion moderated by Morgan Stanley representatives on Wednesday, April 30, 2008 at 3:40 PM (ET) in the Plaza Ballroom.
To access a simultaneous webcast of Mr. Price's overview and discussion via the internet, log on to the "Events & Presentations" section of the Investor Center on Pharmasset's website at http://investor.pharmasset.com/events.cfm. Please connect to the website at least ten minutes prior to the start of the presentation to ensure adequate time for a reliable connection and any software download that may be necessary for the webcast.
A replay of the webcast will be available on Pharmasset's website for thirty days following the conference. The investor presentation, if any, will be available for download in PDF format immediately following the presentation in the "Events & Presentations" section of the Investor Center on Pharmasset's website at http://investor.pharmasset.com/events.cfm.
About Pharmasset
Pharmasset is a clinical-stage pharmaceutical company committed to discovering, developing and commercializing novel drugs to treat viral infections. Pharmasset's primary focus is on the development of oral therapeutics for the treatment of hepatitis B virus (HBV), hepatitis C virus (HCV) and human immunodeficiency virus (HIV).
Pharmasset is currently developing three product candidates. Clevudine,
for the treatment of chronic HBV infection, is enrolling Phase 3 clinical
trials for registration in North, Central and South America and Europe.
Clevudine is already approved for HBV in South Korea and marketed by
Bukwang Pharmaceuticals in South Korea under the brand name Levovir. R7128,
an oral treatment for chronic HCV infection, is in a 4-week Phase 1
clinical trial in combination with Pegasys(R) plus Copegus(R) through a
strategic collaboration with Roche. Racivir, which is being developed for
the treatment of HIV in combination with other approved HIV drugs, has
completed a Phase 2 clinical trial.
Pegasys(R) and Copegus(R) are registered trademarks of Roche.
Contact
Alan Roemer, Vice President
Investor Relations & Corporate Communications
Office: +1 (609) 613-4125
'/>"/>
| SOURCE Pharmasset, Inc. Copyright©2008 PR Newswire. All rights reserved |
Related biology technology :
1. Pharmasset Adds Two Cohorts to R7128 Hepatitis C Study
2. Pharmasset to Present at the Canaccord Adams Hepatitis C Conference on Wednesday, April 9th
3. Pharmasset Receives $10 Million of Working Capital
4. Pharmasset Appoints Herbert J. Conrad as a Director
5. Pharmasset to Present at Cowen & Companys Health Care Conference on Tuesday, March 18th
6. Pharmasset to Present at Susquehannas Second Annual SIGnificant Investment Options in Healthcare Conference on Wednesday, March 5th
7. Pharmasset to Present at the BIO CEO & Investor Conference 2008 on Monday, February 11th
8. Pharmasset Reports Fiscal Year End 2007 Financial Results
9. Pharmasset Appoints Michael Rogers as Chief Development Officer
10. Pharmasset to Present at Three Investor Conferences in November 2007
11. Pharmasset Accesses up to $30 Million of Working Capital
| Copyright © 2003-2012 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |